Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 21 January 1983:
Vol. 219. no. 4582, pp. 310 - 312
DOI: 10.1126/science.6294831
Prev | Table of Contents | Next

Articles

Science, Vol 219, Issue 4582, 310-312
Copyright © 1983 by American Association for the Advancement of Science

articles

Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia

PL Faris, BR Komisaruk, LR Watkins, and DJ Mayer

The endogenous neuropeptide cholecystokinin, when administered systemically or perispinally, potently antagonizes opiate analgesia produced by foot shock and morphine. Nonopiate foot-shock analgesia is not reduced by this neuropeptide. The spinal cord appears to be a critical site of cholecystokinin action. These experiments suggest a physiological role for cholecystokinin as a specific opiate antagonist in analgesia-mediating systems. A similar mode of action may explain other behavioral effects of cholecystokinin, such as suppression of food intake.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance.
J. Y. Xie, D. S. Herman, C.-O. Stiller, L. R. Gardell, M. H. Ossipov, J. Lai, F. Porreca, and T. W. Vanderah (2005)
J. Neurosci. 25, 409-416
   Abstract »    Full Text »    PDF »
Neural Basis for the Hyperalgesic Action of Cholecystokinin in the Rostral Ventromedial Medulla.
M. M. Heinricher and M. J. Neubert (2004)
J Neurophysiol 92, 1982-1989
   Abstract »    Full Text »    PDF »
Chronic Morphine Treatment Modulates the Extracellular Levels of Endogenous Enkephalins in Rat Brain Structures Involved in Opiate Dependence: A Microdialysis Study.
M. M. Nieto, J. Wilson, A. Cupo, B. P. Roques, and F. Noble (2002)
J. Neurosci. 22, 1034-1041
   Abstract »    Full Text »    PDF »
Potentiation of Opioid Analgesia in Dopamine2 Receptor Knock-Out Mice: Evidence for a Tonically Active Anti-Opioid System.
M. A. King, S. Bradshaw, A. H. Chang, J. E. Pintar, and G. W. Pasternak (2001)
J. Neurosci. 21, 7788-7792
   Abstract »    Full Text »    PDF »
Circuitry Underlying Antiopioid Actions of Cholecystokinin Within the Rostral Ventromedial Medulla.
M. M. Heinricher, S. McGaraughty, and V. Tortorici (2001)
J Neurophysiol 85, 280-286
   Abstract »    Full Text »    PDF »
CCK-B/Gastrin Receptor Transmembrane Domain Mutations Selectively Alter Synthetic Agonist Efficacy without Affecting the Activity of Endogenous Peptides.
M. Bläker, Y. Ren, L. Seshadri, E. W. McBride, M. Beinborn, and A. S. Kopin (2000)
Mol. Pharmacol. 58, 399-406
   Abstract »    Full Text »
Effects of Spinal Cholecystokinin Receptor Antagonists on Morphine Antinociception in a Model of Visceral Pain in the Rat.
A. E. Friedrich and G. F. Gebhart (2000)
J. Pharmacol. Exp. Ther. 292, 538-544
   Abstract »    Full Text »
International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors.
F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques (1999)
Pharmacol. Rev. 51, 745-781
   Abstract »    Full Text »    PDF »
Mutations within the Cholecystokinin-B/Gastrin Receptor Ligand `Pocket' Interconvert the Functions of Nonpeptide Agonists and Antagonists.
M. Bläker, Y. Ren, M. C. Gordon, J. E. Hsu, M. Beinborn, and A. S. Kopin (1998)
Mol. Pharmacol. 54, 857-863
   Abstract »    Full Text »
Pentobarbital Antagonism of Morphine Analgesia Mediated by Spinal Cholecystokinin.
J. J. Rady, W. Lin, and J. M. Fujimoto (1998)
J. Pharmacol. Exp. Ther. 284, 878-885
   Abstract »    Full Text »
Prevention of Tolerance to the Antinociceptive Effects of Systemic Morphine by a Selective Cholecystokinin-B Receptor Antagonist in a Rat Model of Peripheral Neuropathy.
J. J. Idänpään-Heikkilä, G. Guilbaud, and V. Kayser (1997)
J. Pharmacol. Exp. Ther. 282, 1366-1372
   Abstract »    Full Text »
Antinociceptive Effects of RB101, a Complete Inhibitor of Enkephalin-catabolizing Enzymes, Are Enhanced by a Cholecystokinin Type B Receptor Antagonist, as Revealed by Noxiously Evoked Spinal c-Fos Expression in Rats.
P. Honoré, J. Buritova, M.-C. Fournié-Zaluski, B. P. Roques, and J.-M. Besson (1997)
J. Pharmacol. Exp. Ther. 281, 208-217
   Abstract »    Full Text »
Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.
E. Wiertelak, S. Maier, and L. Watkins (1992)
Science 256, 830-833
   Abstract »    PDF »
Cholecystokinin Tetrapeptide Induces Panic-like Attacks in Healthy Volunteers: Preliminary Findings.
C. de Montigny (1989)
Arch Gen Psychiatry 46, 511-517
   Abstract »    PDF »
Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin.
P. Faris, C. McLaughlin, C. Baile, J. Olney, and B. Komisaruk (1984)
Science 226, 1215-1217
   Abstract »    PDF »
Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide.
L. Watkins, I. Kinscheck, and D. Mayer (1984)
Science 224, 395-396
   Abstract »    PDF »
Brain Peptides as Intercellular Messengers: Implications for Medicine.
M. R. Brown and L. A. Fisher (1984)
JAMA 251, 1310-1315
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)